BMY Stock — Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co. (BMY)

Updated October 16, 2026.

BMY is a Stock. its distribution rate is 4.22%, its trailing-12-month yield is 4.22%. Dividend Vision Distribution Safety Score™ is 100/100 (Safe). Total return is 23563.4% over the past 54.4 years.

Bristol-Myers Squibb is a biopharmaceutical company that discovers, develops, and commercializes drugs across oncology, hematology, immunology, cardiovascular, and neuroscience indications, with major products including Opdivo for cancer, Eliquis for stroke prevention and blood clots, Revlimid for multiple myeloma, and Orencia for rheumatoid arthritis. The company pays a quarterly distribution with a current yield in the mid-single digits. Bristol-Myers Squibb appeals to income-focused investors seeking exposure to large-cap pharmaceutical companies with established dividend histories.

BMY performance

Price and return data through 2026-10-16.

Total return is 23563.4% over the past 54.4 years. Over the past year its total return — price change plus distributions reinvested — is 43.8%. Its deepest 1-year drawdown was 15.9%.

BMY key facts

Distribution Safety Score™

100 · Safe

Safety-Adjusted Yield

4.22%

Asset type

Stock

Asset class

Equity

Inception date

06/01/1972

Distribution rate

4.22%

Distribution frequency

Quarterly

Trailing yield

4.22%

5-year average yield

3.85

Last close

$59.75 (as of 2026-10-16)

Market cap

$122,052,200,696

Average volume

13770800.0

Dividend

$0.63

Ex-dividend date

10/02/2026

Payment date

11/02/2026

Beta

0.184

Payout ratio

38.7%

P/E ratio

13.16

Forward P/E

9.3633

EPS

$4.54

How Dividend Vision calculates yield and returns

Distribution rate (4.22%) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield (4.22%) is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BMY risks and drawbacks

Payments are quarterly, so cash flow is lumpy versus a monthly fund. The deepest 1-year drawdown on record here is 15.9%.

Who may consider BMY — and who may not

BMY may suit someone looking for a high Distribution Safety Score, moderate current income with a quality tilt. It is a weaker fit for investors who need monthly cash flow (BMY pays quarterly); investors hunting double-digit covered-call yields. This is educational context, not a recommendation to buy or sell.

More on BMY

• ETFs holding BMY
• All tickers starting with B

Tagged: Dividend, Pharmaceutical.

Frequently asked questions